Selective prostacyclin receptor agonism augments glucocorticoid-induced gene expression in human bronchial epithelial cells

Journal of Immunology

Volumn 183, Issue 10, 2009, Pages 6788-6799

  Wilson, Sylvia M ^a   Shen, Pamela ^a,b   Rider, Christopher F ^a   Traves, Suzanne L ^a   Proud, David ^a   Newton, Robert ^a   Giembycz, Mark A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 FLUOROPHENYL) 2 [5 (4 FLUOROPHENYL)BENZOFURAN 2 YLMETHOXYCARBONYLAMINO]PROPIONIC ACID; ADENOVIRUS VECTOR; BENZOFURAN DERIVATIVE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEXAMETHASONE; LUCIFERASE; OLIGONUCLEOTIDE; PROSTACYCLIN RECEPTOR; RO 3244794; TAPROSTENE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHUS MUCOSA; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; EPITHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPORTER GENE;

ANILIDES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOFURANS; BRONCHI; CELL SURVIVAL; CELLS, CULTURED; CYCLIC AMP; DEXAMETHASONE; EPOPROSTENOL; FORSKOLIN; GENE EXPRESSION; GENETIC VECTORS; GLUCOCORTICOIDS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OLIGONUCLEOTIDES; PPAR GAMMA; PROPIONIC ACIDS; RECEPTORS, EPOPROSTENOL; RESPIRATORY MUCOSA; RESPONSE ELEMENTS; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION;

EID: 77952918415     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902738     Document Type: Article

References (75)

1. Vane, J. R., and R. M. Botting. 1995. Pharmacodynamic profile of prostacyclin. Am. J. Cardiol. 75: 3A-10A.
2. Hata, A. N., and R. M. Breyer. 2004. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103: 147-166.
3. Meja, K. K., P. J. Barnes, and M. A. Giembycz. 1997. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-α generation. Br. J. Pharmacol. 122: 149-157.
4. 2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. J. Immunol. 169: 5997-6004.
5. 2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells. J. Leukocyte Biol. 81: 809-887.
6. 2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J. Immunol. 178: 702-710.
7. Ayer, L. M., S. M. Wilson, S. L. Traves, D. Proud, and M. A. Giembycz. 2008. (4,5-Dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxy-benzyl)-phenyl]-amine (RO1138452) is a selective, pseudo-irreversible orthosteric antagonist at the prostacyclin (IP)-receptor expressed by human airway epithelial cells: negative IP-receptor-mediated regulation of CXCL9 and CXCL10 release. J. Pharmacol. Exp. Ther. 324: 815-826.
8. Clarke, D. L., M. G. Belvisi, S. J. Smith, E. Hardaker, M. H. Yacoub, K. K. Meja, R. Newton, D. M. Slater, and M. A. Giembycz. 2005. Prostanoid receptor expression by human airway smooth muscle cells and regulation of the secretion of granulocyte colony-stimulating factor. Am. J. Physiol. 288: L238-L250.
9. Walch, L., C. Labat, J. P. Gascard, M. de, V., C. Brink, and X. Norel. 1999. Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br. J. Pharmacol. 126: 859-866. (Pubitemid 29103701)
10. 3, and FP prostanoid receptors are involved. Int. Immunopharmacol. 3: 865-878.
11. Takahashi, Y., S. Tokuoka, T. Masuda, Y. Hirano, M. Nagao, H. Tanaka, N. Inagaki, S. Narumiya, and H. Nagai. 2002. Augmentation of allergic inflammation in prostanoid IP-receptor deficient mice. Br. J. Pharmacol. 137: 315-322.
12. 2 in airway remodeling induced by repeated allergen challenge in mice. Am. J. Respir. Cell Mol. Biol. 29: 314-320.
13. + Th2 cells into the airways in a mouse model of asthma. J. Immunol. 179: 6193-6203.
14. Idzko, M., H. Hammad, M. van Nimwegen, M. Kool, N. Vos, H. C. Hoogsteden, and B. N. Lambrecht. 2007. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J. Clin. Invest. 117: 464-472.
15. Chen, Y., M. Hanaoka, P. Chen, Y. Droma, N. F. Voelkel, and K. Kubo. 2009. Protective effect of beraprost sodium, a stable prostacyclin analog, in the development of cigarette smoke extract-induced emphysema. Am. J. Physiol. 296: L648-L656.
16. 2 receptor IP protects against respiratory syncytial virus-induced illness. J. Virol. 78: 10303-10309.
17. Traves, S. L., and D. Proud. 2007. Viral-associated exacerbations of asthma and COPD. Curr. Opin. Pharmacol. 7: 252-258.
18. Suissa, S., R. McGhan, D. Niewoehner, and B. Make. 2007. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc. Am. Thor. Soc. 4: 535-542.
19. De Bosscher, K., W. Vanden Berghe, and G. Haegeman. 2003. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24: 488-522.
20. 2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol. Pharmacol. 73: 201-214.
21. Newton, R., and N. S. Holden. 2007. Separating transrepression and transactivation: A distressing divorce for the glucocorticoid receptor? Mol. Pharmacol. 72: 799-809.
22. Clark, A. R., J. R. S. Martins, and C. R. Tchen. 2008. Role of dual specificity phosphatases in biological responses to glucocorticoids. J. Biol. Chem. 283: 25765-25769.
23. Clark, A. R. 2007. Anti-inflammatory functions of glucocorticoid-induced genes. Mol. Cell. Endocrinol. 275: 79-97.
24. Nordeen, S. K., M. L. Moyer, and B. J. Bona. 1994. The coupling of multiple signal transduction pathways with steroid response mechanisms. Endocrinology 134: 1723-1732.
25. Churchill, L., F. H. Chilton, J. H. Resau, R. Bascom, W. C. Hubbard, and D. Proud. 1989. Cyclooxygenase metabolism of endogenous arachidonic acid by cultured human tracheal epithelial cells. Am. Rev. Respir. Dis. 140: 449-459. (Pubitemid 19218364)
26. Chivers, J. E., L. M. Cambridge, M. C. Catley, J. C. Mak, L. E. Donnelly, P. J. Barnes, and R. Newton. 2004. Differential effects of RU486 reveal distinct mechanisms for glucocorticoid repression of prostaglandin E release. Eur. J. Biochem. 271: 4042-4052.
27. Bley, K. R., A. Bhattacharya, D. V. Daniels, J. Gever, A. Jahangir, C. O'Yang, S. Smith, D. Srinivasan, A. P. Ford, and M. F. Jett. 2006. RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br. J. Pharmacol. 147: 335-345.
28. Meja, K., M. C. Catley, L. M. Cambridge, P. J. Barnes, H. Lum, R. Newton, and M. A. Giembycz. 2004. Adenovirus-mediated delivery and expression of a cAMP-dependent protein kinase inhibitor gene to BEAS-2B epithelial cells abolishes the anti-inflammatory effects of rolipram, salbutamol and prostaglandin E2: a comparison with H-89. J. Pharmacol. Exp. Ther. 309: 833-844.
29. Leesnitzer, L. M., D. J. Parks, R. K. Bledsoe, J. E. Cobb, J. L. Collins, T. G. Consler, R. G. Davis, E. A. Hull-Ryde, J. M. Lenhard, L. Patel, et al. 2002. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41: 6640-6650.
30. Waud, D. R., S. L. Son, and B. E. Waud. 1978. Kinetic and empirical analysis of dose-response curves illustrated with a cardiac example. Life Sci. 22: 1275-1285.
31. Schneider, J., E. Friderichs, B. Kogel, U. Seipp, H.-J. Stahlberg, R. Terlinden, and K. Heintze. 1993. Taprostene sodium. Cardiovasc. Drug Rev. 11: 479-500.
32. Aksoy, M. O., X.-x. Li, M. Borenstein, Y. Yi, and S. G. Kelsen. 1999. Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. J. Allergy. Clin. Immunol. 103: 1081-1091.
33. Neubig, R. R., M. Spedding, T. Kenakin, and A. Christopoulos. 2003. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 55: 597-606.
34. Wise, H., and R. L. Jones. 1996. Focus on prostacyclin and its novel mimetics. Trends Pharmacol. Sci. 17: 17-21.
35. Chow, K. B., R. L. Jones, and H. Wise. 2004. Agonists can discriminate between cloned human and mouse prostacyclin receptors. Prostaglandins Leukot. Essent. Fatty Acids 70: 423-429.
36. Falcetti, E., D. M. Flavell, B. Staels, A. Tinker, S. G. Haworth, and L. H. Clapp. 2007. IP-receptor-dependent activation of PPARγ by stable prostacyclin analogues. Biochem. Biophys. Res. Commun. 360: 821-827.
37. Mittelstadt, P. R., and J. D. Ashwell. 2001. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. J. Biol. Chem. 276: 29603-29610.
38. Eddleston, J., J. Herschbach, A. L. Wagelie-Steffen, S. C. Christiansen, and B. L. Zuraw. 2007. The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells. J. Allergy Clin. Immunol. 119: 115-122.
39. Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Mol. Endocrinol. 13: 1811-1822.
40. Issa, R., S. Xie, N. Khorasani, M. Sukkar, I. M. Adcock, K. Y. Lee, and K. F. Chung. 2007. Corticosteroid inhibition of growth-related oncogene protein-α via mitogen-activated kinase phosphatase-1 in airway smooth muscle cells. J. Immunol. 178: 7366-7375.
41. Abramovitz, M., M. Adam, Y. Boie, M. Carriere, D. Denis, C. Godbout, S. Lamontagne, C. Rochette, N. Sawyer, N. M. Tremblay, et al. 2000. The use of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta. 1483: 285-293.
42. Wise, H., and R. L. Jones. 2000. Prostacyclin and Its Receptors. Kluwer Academic Publishers, Hingham, MA.
43. Jones, R. L., M. A. Giembycz, and D. F. Woodward. 2009. Prostanoid receptor antagonists: development and therapeutic applications. Br. J. Pharmacol. 158: 104-145.
44. Kip2. J. Mol. Endocrinol. 30: 359-368.
45. van der Laan, S., R. A. Sarabdjitsingh, M. F. Van Batenburg, S. B. Lachize, H. Li, T. F. Dijkmans, E. Vreugdenhil, E. R. de Kloet, and O. C. Meijer. 2008. Chromatin immunoprecipitation scanning identifies glucocorticoid receptor binding regions in the proximal promoter of a ubiquitously expressed glucocorticoid target gene in brain. J. Neurochem. 106: 2515-2523.
46. Hogg, J. C., F. Chu, S. Utokaparch, R. Woods, W. M. Elliott, L. Buzatu, R. M. Cherniack, R. M. Rogers, F. C. Sciurba, H. O. Coxson, and P. D. Pare. 2004. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350: 2645-2653.
47. KIP2 modulates stress-activated signaling by inhibiting c-Jun NH2-terminal kinase/stress-activated protein Kinase. J. Biol. Chem. 278: 48092-48098.
48. So, A. Y., C. Chaivorapol, E. C. Bolton, H. Li, and K. R. Yamamoto. 2007. Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS. Genet. 3: e94.
49. Yeagley, D., and P. G. Quinn. 2005. 3′,5′-Cyclic adenosine monophosphate response element-binding protein and CCAAT enhancer-binding protein are dispensable for insulin inhibition of phosphoenolpyruvate carboxykinase transcription and for its synergistic induction by protein kinase A and glucocorticoids. Mol. Endocrinol. 19: 913-924.
50. Schmoll, D., C. Wasner, C. J. Hinds, B. B. Allan, R. Walther, and A. Burchell. 1999. Identification of a cAMP response element within the glucose-6-phosphatase hydrolytic subunit gene promoter which is involved in the transcriptional regulation by cAMP and glucocorticoids in H4IIE hepatoma cells. Biochem. J. 338: 457-463.
51. van Schaftingen, E., and I. Gerin. 2002. The glucose-6-phosphatase system. Biochem. J. 362: 513-532.
52. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. 274: 1005-1010.
53. Usmani, O. S., K. Ito, K. Maneechotesuwan, M. Ito, M. Johnson, P. J. Barnes, and I. M. Adcock. 2005. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit Care Med. 172: 704-712.
54. Profita, M., R. Gagliardo, R. Di Giorgi, F. Pompeo, M. Gjomarkaj, G. Nicolini, J. Bousquet, and A. M. Vignola. 2005. Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy 60: 323-329.
55. 2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360: 1293-1299.
56. Rangarajan, P. N., K. Umesono, and R. M. Evans. 1992. Modulation of glucocorticoid receptor function by protein kinase A. Mol. Endocrinol. 6: 1451-1457.
57. Oikarinen, J., L. Hamalainen, and A. Oikarinen. 1984. Modulation of glucocorticoid receptor activity by cyclic nucleotides and its implications on the regulation of human skin fibroblast growth and protein synthesis. Biochim. Biophys. Acta 799: 158-165.
58. Espinas, M. L., J. Roux, R. Pictet, and T. Grange. 1995. Glucocorticoids and protein kinase A coordinately modulate transcription factor recruitment at a glucocorticoid-responsive unit. Mol. Cell. Biol. 15: 5346-5354.
59. Rowan, B. G., N. Garrison, N. L. Weigel, and B. W. O'Malley. 2000. 8-Bromocyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligandindependent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol. Cel.l Biol. 20: 8720-8730.
60. Fenne, I. S., T. Hoang, M. Hauglid, J. V. Sagen, E. A. Lien, and G. Mellgren. 2008. Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 3′,5′-cyclic adenosine 5′-monophosphate-dependent protein kinase. Endocrinology 149: 4336-4345.
61. Hoang, T., I. S. Fenne, C. Cook, B. Borud, M. Bakke, E. A. Lien, and G. Mellgren. 2004. cAMP-dependent protein kinase regulates ubiquitin-proteasome- mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. J. Biol. Chem. 279: 49120-49130.
62. Barnes, P. J. 2008. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 8: 183-192.
63. Sin, D. D., and S. F. Man. 2007. Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients? Curr. Opin. Pulm. Med. 13: 90-97.
64. Peinado, V. I., S. Pizarro, and J. A. Barbera. 2008. Pulmonary vascular involvement in COPD. Chest 134: 808-814.
65. Chaouat, A., R. Naeije, and E. Weitzenblum. 2008. Pulmonary hypertension in COPD. Eur. Respir. J. 32: 1371-1385.
66. Mitchell, R. S., G. W. Silvers, G. A. Dart, T. L. Petty, T. N. Vincent, S. F. Ryan, and G. F. Filley. 1968. Clinical and morphologic correlations in chronic airway obstruction. Aspen. Emphysema. Conf. 9: 109-123.
67. Ferroni, P., S. Basili, F. Martini, M. Vieri, G. Labbadia, C. Cordova, C. Alessandri, and P. P. Gazzaniga. 2000. Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. J. Investig. Med. 48: 21-27.
68. Cordova, C., A. Musca, F. Violi, C. Alessandri, A. Perrone, and F. Balsano. 1985. Platelet hyperfunction in patients with chronic airways obstruction. Eur. J. Respir. Dis. 66: 9-12. (Pubitemid 15192903)
69. Nana-Sinkam, S. P., J. D. Lee, S. Sotto-Santiago, R. S. Stearman, R. L. Keith, Q. Choudhury, C. Cool, J. Parr, M. D. Moore, T. M. Bull, et al. 2007. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am. J. Respir. Crit Care Med. 175: 676-685.
70. Davi, G., S. Basili, M. Vieri, F. Cipollone, S. Santarone, C. Alessandri, P. Gazzaniga, C. Cordova, and F. Violi. 1997. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. Am. J. Respir. Crit Care Med. 156: 1794-1799.
71. Beghetti, M., G. Reber, M. P. de, L. Vadas, A. Chiappe, I. Spahr-Schopfer, and P. C. Rimensberger. 2002. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur. Respir. J. 19: 518-524.
72. McLaughlin, V. V., A. Shillington, and S. Rich. 2002. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106: 1477-1482.
73. Norel, X., L. Walch, C. Labat, J. P. Gascard, E. Dulmet, and C. Brink. 1999. Prostanoid receptors involved in the relaxation of human bronchial preparations. Br. J. Pharmacol. 126: 867-872. (Pubitemid 29103702)
74. Oudiz, R. J., and H. W. Farber. 2009. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am. Heart J. 157: 625-635.
75. Kuwano, K., A. Hashino, T. Asaki, T. Hamamoto, T. Yamada, K. Okubo, and K. Kuwabara. 2007. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N- (methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J. Pharmacol. Exp. Ther. 322: 1181-1188.